Novartis AG (NVS): Price and Financial Metrics

Novartis AG (NVS): $74.32

-1.69 (-2.22%)

POWR Rating

Component Grades














  • Stability is the dimension where NVS ranks best; there it ranks ahead of 98.18% of US stocks.
  • NVS's strongest trending metric is Quality; it's been moving down over the last 179 days.
  • NVS ranks lowest in Momentum; there it ranks in the 17th percentile.

NVS Stock Summary

  • With a market capitalization of $177,268,700,000, NOVARTIS AG has a greater market value than 99.11% of US stocks.
  • Over the past twelve months, NVS has reported earnings growth of 119.03%, putting it ahead of 87.05% of US stocks in our set.
  • In terms of volatility of its share price, NVS is more volatile than only 1.42% of stocks we're observing.
  • Stocks that are quantitatively similar to NVS, based on their financial statements, market capitalization, and price volatility, are AZN, CSCO, TXN, BMY, and RTX.
  • Visit NVS's SEC page to see the company's official filings. To visit the company's web site, go to

NVS Valuation Summary

  • NVS's price/earnings ratio is 7.3; this is 62.76% lower than that of the median Healthcare stock.
  • Over the past 243 months, NVS's price/sales ratio has gone down 2.8.

Below are key valuation metrics over time for NVS.

Stock Date P/S P/B P/E EV/EBIT
NVS 2022-09-23 3.2 2.7 7.3 7.6
NVS 2022-09-22 3.2 2.7 7.4 7.7
NVS 2022-09-21 3.2 2.7 7.4 7.7
NVS 2022-09-20 3.3 2.8 7.6 7.9
NVS 2022-09-19 3.4 2.8 7.7 8.0
NVS 2022-09-16 3.4 2.8 7.7 8.0

NVS Growth Metrics

    Its 3 year cash and equivalents growth rate is now at 103.5%.
  • Its 2 year revenue growth rate is now at 6.14%.
  • Its year over year net income to common stockholders growth rate is now at 204.01%.
Over the past 70 months, NVS's revenue has gone up $3,154,000,000.

The table below shows NVS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-06-30 52,788 14,213 22,982
2022-03-31 52,997 14,590 24,184
2021-12-31 52,877 15,071 24,021
2021-09-30 52,385 15,192 9,807
2021-06-30 51,556 13,423 8,984
2021-03-31 49,884 13,252 7,955

NVS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • NVS has a Quality Grade of B, ranking ahead of 86.01% of graded US stocks.
  • NVS's asset turnover comes in at 0.42 -- ranking 108th of 682 Pharmaceutical Products stocks.
  • GHSI, KALA, and ADAP are the stocks whose asset turnover ratios are most correlated with NVS.

The table below shows NVS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.420 0.693 0.212
2021-06-30 0.406 0.691 0.194
2021-03-31 0.393 0.691 0.176
2020-12-31 0.392 0.697 0.182
2020-09-30 0.401 0.700 0.174
2020-06-30 0.412 0.699 0.180

NVS Stock Price Chart Interactive Chart >

Price chart for NVS

NVS Price/Volume Stats

Current price $74.32 52-week high $94.26
Prev. close $76.01 52-week low $74.15
Day low $74.16 Volume 1,453,585
Day high $75.07 Avg. volume 2,423,113
50-day MA $83.23 Dividend yield 2.84%
200-day MA $85.84 Market Cap 164.44B

Novartis AG (NVS) Company Bio

Novartis AG offers patented prescription medicines in various therapeutic areas, such as oncology, cardio-metabolic, immunology and dermatology, retina, respiratory, neuroscience, and established medicines. The company was founded in 1895 and is based in Basel, Switzerland.

NVS Latest News Stream

Event/Time News Detail
Loading, please wait...

NVS Latest Social Stream

Loading social stream, please wait...

View Full NVS Social Stream

Latest NVS News From Around the Web

Below are the latest news stories about NOVARTIS AG that investors may wish to consider to help them evaluate NVS as an investment opportunity.

Ionis' (IONS) Hypercholesterolemia Drug Not to Enter Phase III

Ionis (IONS) posts data from the phase IIb SOLANO study on ION449 for treating hypercholesterolemia. Though the study met the primary endpoint, ION449 will not advance into phase III development.

Yahoo | September 23, 2022

Novartis (NVS) to Focus on US Markets Backed by 8 Key Drugs

Novartis (NVS) unveils a new focused strategy with the spotlight on the US markets driven by eight key brands that are expected to have a multi-billion dollar peak sales potential.

Yahoo | September 23, 2022

Novartis outlines plan to become a 'top-five player' in U.S. pharmaceuticals market

Novartis AG on Thursday told investors that the Swiss drug maker plans to adopt a "U.S.-first mindset" in its bid to become a "top-five player" in the U.S. market by 2027. Novartis is one of the world's largest pharmaceutical companies; however in the U.S., it was the tenth largest by revenue in the U.S. in 2021,

Yahoo | September 23, 2022

Strength Seen in Lilly (LLY): Can Its 4.9% Jump Turn into More Strength?

Lilly (LLY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Yahoo | September 23, 2022

7 Safe Havens All Investors Should Have Exposure to in 2022

Few stocks with deep value and growth prospects offer upside and safe havens for investors, with those picks the exception.

Chris Lau on InvestorPlace | September 22, 2022

Read More 'NVS' Stories Here

NVS Price Returns

1-mo -10.11%
3-mo -11.70%
6-mo -15.51%
1-year -8.00%
3-year -8.47%
5-year 13.77%
YTD -12.78%
2021 -5.12%
2020 2.08%
2019 28.03%
2018 5.95%
2017 18.80%

NVS Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full NVS Dividend History

Continue Researching NVS

Want to see what other sources are saying about Novartis Ag's financials and stock price? Try the links below:

Novartis Ag (NVS) Stock Price | Nasdaq
Novartis Ag (NVS) Stock Quote, History and News - Yahoo Finance
Novartis Ag (NVS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6416 seconds.